Lachlan MacKinnon (L) and Adrian Woolfson (Replay)

Un­der hub-and-spoke biotech, se­r­i­al founders launch new start­up hop­ing to make gene ther­a­pies for the eye

In late Ju­ly, Sang­amo’s for­mer R&D chief Adri­an Woolf­son, who left the biotech when it split its R&D, launched his own gene ther­a­py out­fit …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA